查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1636731

2030 年患者衍生异质骨移植模型市场预测：按模型类型、肿瘤类型、植入方法、应用、最终用户和地区进行的全球分析

Patient-derived Xenograft Model Market Forecasts to 2030 - Global Analysis By Model Type, Tumor Type, Implantation Method, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，到 2024 年，患者来源的异质骨移植模型的全球市场价值将达到 4.943 亿美元，预测期内复合年增长率为 14.3%，到 2030 年将达到 11.023 亿美元。

在称为患者源性异质骨移植（PDX）模型的实验系统中，来自人类患者的肿瘤组织被移植到免疫力缺乏小鼠。该模型是癌症研究中的有用工具，因为原始肿瘤的遗传特征和表型得以保留。与传统的细胞株模型相比，PDX 模型可以更真实地描述人类癌症，并用于研究肿瘤生物学、测试疗法和创建个人化医疗策略。

根据丹娜—法伯癌症研究所的一项研究，在 29 名晚期肉瘤患者中，有 16 名患者成功建立了 PDX 模型。

个人化医疗需求不断成长

对个人化医疗的需求不断增长正在推动患者来源的异质骨移植（PDX）模型市场。 PDX 模型使研究人员能够研究患者特定的癌症生物学和药物反应，这对于根据个别基因谱量身订做治疗方案至关重要。这种方法提高了治疗效果并减少了副作用。癌症发生率的增加和基因组学的进步进一步增加了对个人化医疗的需求。

开发和维护成本高

建立和维护 PDX 模型需要大量的财务资源、专业知识和复杂的基础设施。肿瘤植入和维持的复杂过程限制了其在小型研究机构中的使用。此外，免疫力缺乏动物和人类肿瘤样本的高成本进一步增加了成本。这些经济障碍对广泛采用提出了挑战。

癌症研究进展

癌症研究的进步正在为 PDX 模型市场创造机会。基于 CRISPR 的基因编辑、人工智慧主导的资料分析和人性化 PDX 模型等创新正在提高临床前研究的准确性和效率。这些进步使研究人员能够探索新的治疗标靶，改善生物标记的发现，并加速药物开发过程。此外，公共和私人对肿瘤学研究投资的增加正在推动对先进 PDX 模型的需求。

道德问题和监管挑战

道德问题和监管挑战威胁着 PDX 模型市场的成长。在研究中使用动物会引发伦理问题，并导致制定严格的指导方针，从而减缓或限制研究。 FDA 等监管机构正在采取措施减少对动物模型的依赖，这可能会影响市场动态。这些挑战需要遵守复杂的通讯协定，并增加研究机构的营运成本和时限。

COVID-19 的影响：

由于实验室营运、供应链和研究资金的中断，COVID-19 的爆发对 PDX 模型市场产生了负面影响。由于资源被转用于 COVID-19 研究，许多肿瘤学研究被推迟。然而，这场大流行强调了个人化医疗的重要性，并强调了 PDX 模型在癌症研究中的重要性。一旦限制放鬆，人们重新专注于创新的癌症治疗方法，需求就会反弹。

预计滑鼠模型产业在预测期内将是最大的。

预计滑鼠模型部分在预测期内将占据最大的市场占有率。小鼠被广泛使用，因为它们与人类基因相似，易于处理，并且与其他动物相比具有成本效益。小鼠提供了一个强大的平台来研究体内肿瘤生长、药物疗效和抗药性机制。基于小鼠的 PDX 模型已建立协议，进一步支持其在临床前肿瘤学研究中的优势。

生物样本库产业预计在预测期内复合年增长率最高。

在预测期内，生物银行产业预计将出现最高的复合年增长率，因为它负责保存源自患者的肿瘤样本以供将来使用。生物库允许研究人员取得不同的肿瘤检体，以开发新的 PDX 模型和回顾性研究。此功能加快了药物发现过程，同时确保了实验的可重复性。对个人化医疗的日益重视增加了对生物样本库服务作为临床前研究基础设施重要组成部分的需求。

比最大的地区

预计北美地区在预测期内将占据最大的市场占有率。高癌症发病率、先进的医疗基础设施以及对癌症研究的大量公共和私人投资等因素正在推动该地区的成长。主要产业参与者的出现进一步巩固了北美在 PDX 模型采用方面的领导地位。此外，政府对精准医疗的支持也为此优势做出了重大贡献。

复合年增长率最高的地区：

预计亚太地区在预测期内将实现最高成长率。快速的都市化、不断增加的医疗支出和不断上升的癌症发病率正在推动该地区对 PDX 模型等先进研究工具的需求。向现代医疗保健的转变使亚太地区成为主要的成长中心。此外，中国和印度等国家正大力投资生技和药物研发，促进市场扩张。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场公司的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争标基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球病患异质骨移植模型市场：依模型类型

  • 小鼠模型
    • 诺德SCID模型
    • 核子供应国集团模型
    • 其他免疫力缺乏模型
  • 大鼠模型
    • 免疫力缺乏大鼠模型
    • 人源化大鼠模型

第六章全球患​​者异质骨移植模型市场：按肿瘤类型

  • 胃肠道肿瘤
  • 妇科肿瘤
  • 呼吸道肿瘤
  • 乳癌肿瘤
  • 血液肿瘤
  • 泌尿系统肿瘤
  • 神经肿瘤
  • 其他肿瘤类型

第七章全球病患衍生异质骨移植模型市场：依移植方法分类

  • 皮下的
  • 原位
    • 手术植入
    • 非手术植入

第八章全球患者异质骨移植模型市场：依应用分类

  • 临床前药物开发
  • 生物标记分析
  • 生物银行
  • 转化研究

第九章全球病患衍生异质骨移植模型市场：依最终使用者分类

  • 製药和生物技术公司
  • 学术/研究机构
  • 合约研究组织

第十章全球患者源性异质骨移植模型市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东/非洲

第十一章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务拓展
  • 其他关键策略

第十二章 公司概况

  • Champions Oncology
  • Charles River Laboratories
  • Crown Bioscience
  • EPO Berlin-Buch
  • Hera BioLabs
  • Horizon Discovery Group
  • Inotiv
  • JSR Corporation
  • Oncodesign Precision Medicine
  • Pharmatest Services
  • Taconic Biosciences
  • The Jackson Laboratory
  • Urolead
  • WuXi AppTec
  • Xenopat
  • Xentech
Product Code: SMRC28372

According to Stratistics MRC, the Global Patient-derived Xenograft Model Market is accounted for $494.3 million in 2024 and is expected to reach $1102.3 million by 2030 growing at a CAGR of 14.3% during the forecast period. An experimental system known as a patient-derived xenograft (PDX) model involves implanting tumor tissues from human patients into immunocompromised mice. This model is a useful tool for cancer research because it maintains the original tumor's genetic and phenotypic features. Compared to conventional cell line models, PDX models provide a more realistic depiction of human cancer and are utilized to investigate tumor biology, test therapeutic medications, and create personalized medicine strategies.

According to Dana-Farber Cancer Institute study, 16 out of 29 patients with advanced sarcoma successfully established PDX models.

Market Dynamics:

Driver:

Rising demand for personalized medicine

The rising demand for personalized medicine is driving the patient-derived xenograft (PDX) model market. PDX models enable researchers to study patient-specific cancer biology and drug responses, making them essential for tailoring treatments to individual genetic profiles. This approach improves therapeutic efficacy and reduces adverse effects, aligning with the growing focus on precision oncology. The increasing prevalence of cancer and advancements in genomics further amplify the need for personalized medicine.

Restraint:

High costs of development and maintenance

Establishing and sustaining PDX models require significant financial resources, specialized expertise, and advanced infrastructure. The complex processes involved in tumor implantation and maintenance limit accessibility for smaller research organizations. Additionally, the high cost of immunodeficient animals and human tumor samples further increases expenses. These financial barriers pose challenges to widespread adoption.

Opportunity:

Advancements in cancer research

Advancements in cancer research are creating opportunities for the PDX model market. Innovations such as CRISPR-based gene editing, AI-driven data analysis and humanized PDX models are enhancing the accuracy and efficiency of preclinical studies. These advancements allow researchers to explore novel therapeutic targets, improve biomarker discovery, and accelerate drug development processes. Additionally, increasing public and private investments in oncology research are driving demand for advanced PDX models.

Threat:

Ethical concerns and regulatory challenges

Ethical concerns and regulatory challenges threaten the growth of the PDX model market. The use of animals in research raises ethical issues, leading to stringent guidelines that can delay or restrict studies. Regulatory agencies like the FDA have introduced measures to reduce reliance on animal models, potentially affecting market dynamics. These challenges necessitate compliance with complex protocols, increasing operational costs and timeframes for research organizations.

Covid-19 Impact:

The COVID-19 pandemic negatively impacted the PDX model market due to disruptions in laboratory operations, supply chains, and research funding. Many oncology studies were delayed as resources were diverted toward COVID-19 research. However, the pandemic underscored the importance of personalized medicine, highlighting the relevance of PDX models in cancer research. As restrictions eased, demand rebounded with renewed focus on innovative cancer therapies.

The mice models segment is expected to be the largest during the forecast period

The mice models segment is expected to account for the largest market share during the forecast period. Mice are widely used due to their genetic similarity to humans, ease of handling, and cost-effectiveness compared to other animals. They provide a robust platform for studying tumor growth, drug efficacy, and resistance mechanisms in vivo. The availability of well-established protocols for mice-based PDX models further supports their dominance in preclinical oncology research.

The biobanking segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the biobanking segment is expected to witness the highest CAGR due to its role in preserving patient-derived tumor samples for future use. Biobanks enable researchers to access diverse tumor specimens for developing new PDX models and conducting retrospective studies. This capability accelerates drug discovery processes while ensuring reproducibility in experiments. The growing emphasis on personalized medicine drives demand for biobanking services as an essential component of preclinical research infrastructure.

Region with largest share:

The North America region is anticipated to account for the largest market share during the forecast period. Factors such as a high prevalence of cancer, advanced healthcare infrastructure, and significant public-private investments in oncology research drive regional growth. The presence of key industry players further strengthens North America's position as a leader in PDX model adoption. Additionally, government initiatives supporting precision medicine also contribute significantly to this dominance.

Region with highest CAGR:

The Asia Pacific region is anticipated to register the highest growth rate over the forecast period. Rapid urbanization, increasing healthcare expenditure, and rising cancer incidence drive demand for advanced research tools like PDX models in this region. The shift toward modern healthcare practices positions Asia Pacific as a key growth hub. Furthermore, countries like China and India are investing heavily in biotechnology and pharmaceutical R&D, fostering market expansion.

Key players in the market

Some of the key players in Patient-derived Xenograft Model Market include Champions Oncology, Charles River Laboratories, Crown Bioscience, EPO Berlin-Buch, Hera BioLabs, Horizon Discovery Group, Inotiv, JSR Corporation, Oncodesign Precision Medicine, Pharmatest Services, Taconic Biosciences, The Jackson Laboratory, Urolead, WuXi AppTec, Xenopat and Xentech.

Key Developments:

In December 2024, Can-Fite BioPharma Ltd. recently announced that its work titled The Liver Protective Effect of the Anti-Cancer Drug Candidate Namodenoson is mediated via Adiponectin will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium to take place at San Francisco & On Line, January 23-25.

In October 2019, Crown Bioscience announced the launch of a new tumor organoid drug development platform with the potential to significantly improve the predictivity and speed of preclinical drug discovery. The initial phase of the platform launch features the first commercially available 3D in vitro PDX-derived organoid (PDXO) models generated from CrownBio's uniquely-characterized library of 2500+ patient-derived xenograft (PDX) models.

In May 2015, Taconic Biosciences and Cellaria Biosciences have entered into a scientific collaboration designed to improve the utility of patient-derived xenografts (PDXs) in animal models for oncology and immuno-oncology research. Cellaria's novel methodologies for generating cells from patient tumors will complement Taconic's industry-leading portfolio of tissue humanized mouse models, which are said to be well suited as hosts for PDXs.

Model Types Covered:

  • Mice Models
  • Rat Models

Tumor Types Covered:

  • Gastrointestinal Tumors
  • Gynecological Tumors
  • Respiratory Tumors
  • Breast Cancer Tumors
  • Hematological Tumors
  • Urological Tumors
  • Neurological Tumors
  • Other Tumor Types

Implantation Methods Covered:

  • Subcutaneous
  • Orthotopic

Applications Covered:

  • Preclinical Drug Development
  • Biomarker Analysis
  • Biobanking
  • Translational Research

End Users Covered:

  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutions
  • Contract Research Organizations

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Patient-derived Xenograft Model Market, By Model Type

  • 5.1 Introduction
  • 5.2 Mice Models
    • 5.2.1 NOD SCID Models
    • 5.2.2 NSG Models
    • 5.2.3 Other Immunodeficient Models
  • 5.3 Rat Models
    • 5.3.1 Immunodeficient Rat Models
    • 5.3.2 Humanized Rat Models

6 Global Patient-derived Xenograft Model Market, By Tumor Type

  • 6.1 Introduction
  • 6.2 Gastrointestinal Tumors
  • 6.3 Gynecological Tumors
  • 6.4 Respiratory Tumors
  • 6.5 Breast Cancer Tumors
  • 6.6 Hematological Tumors
  • 6.7 Urological Tumors
  • 6.8 Neurological Tumors
  • 6.9 Other Tumor Types

7 Global Patient-derived Xenograft Model Market, By Implantation Method

  • 7.1 Introduction
  • 7.2 Subcutaneous
  • 7.3 Orthotopic
    • 7.3.1 Surgical Implantation
    • 7.3.2 Non-surgical Implantation

8 Global Patient-derived Xenograft Model Market, By Application

  • 8.1 Introduction
  • 8.2 Preclinical Drug Development
  • 8.3 Biomarker Analysis
  • 8.4 Biobanking
  • 8.5 Translational Research

9 Global Patient-derived Xenograft Model Market, By End User

  • 9.1 Introduction
  • 9.2 Pharmaceutical & Biotechnology Companies
  • 9.3 Academic & Research Institutions
  • 9.4 Contract Research Organizations

10 Global Patient-derived Xenograft Model Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Champions Oncology
  • 12.2 Charles River Laboratories
  • 12.3 Crown Bioscience
  • 12.4 EPO Berlin-Buch
  • 12.5 Hera BioLabs
  • 12.6 Horizon Discovery Group
  • 12.7 Inotiv
  • 12.8 JSR Corporation
  • 12.9 Oncodesign Precision Medicine
  • 12.10 Pharmatest Services
  • 12.11 Taconic Biosciences
  • 12.12 The Jackson Laboratory
  • 12.13 Urolead
  • 12.14 WuXi AppTec
  • 12.15 Xenopat
  • 12.16 Xentech

List of Tables

  • Table 1 Global Patient-derived Xenograft Model Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Patient-derived Xenograft Model Market Outlook, By Model Type (2022-2030) ($MN)
  • Table 3 Global Patient-derived Xenograft Model Market Outlook, By Mice Models (2022-2030) ($MN)
  • Table 4 Global Patient-derived Xenograft Model Market Outlook, By NOD SCID Models (2022-2030) ($MN)
  • Table 5 Global Patient-derived Xenograft Model Market Outlook, By NSG Models (2022-2030) ($MN)
  • Table 6 Global Patient-derived Xenograft Model Market Outlook, By Other Immunodeficient Models (2022-2030) ($MN)
  • Table 7 Global Patient-derived Xenograft Model Market Outlook, By Rat Models (2022-2030) ($MN)
  • Table 8 Global Patient-derived Xenograft Model Market Outlook, By Immunodeficient Rat Models (2022-2030) ($MN)
  • Table 9 Global Patient-derived Xenograft Model Market Outlook, By Humanized Rat Models (2022-2030) ($MN)
  • Table 10 Global Patient-derived Xenograft Model Market Outlook, By Tumor Type (2022-2030) ($MN)
  • Table 11 Global Patient-derived Xenograft Model Market Outlook, By Gastrointestinal Tumors (2022-2030) ($MN)
  • Table 12 Global Patient-derived Xenograft Model Market Outlook, By Gynecological Tumors (2022-2030) ($MN)
  • Table 13 Global Patient-derived Xenograft Model Market Outlook, By Respiratory Tumors (2022-2030) ($MN)
  • Table 14 Global Patient-derived Xenograft Model Market Outlook, By Breast Cancer Tumors (2022-2030) ($MN)
  • Table 15 Global Patient-derived Xenograft Model Market Outlook, By Hematological Tumors (2022-2030) ($MN)
  • Table 16 Global Patient-derived Xenograft Model Market Outlook, By Urological Tumors (2022-2030) ($MN)
  • Table 17 Global Patient-derived Xenograft Model Market Outlook, By Neurological Tumors (2022-2030) ($MN)
  • Table 18 Global Patient-derived Xenograft Model Market Outlook, By Other Tumor Types (2022-2030) ($MN)
  • Table 19 Global Patient-derived Xenograft Model Market Outlook, By Implantation Method (2022-2030) ($MN)
  • Table 20 Global Patient-derived Xenograft Model Market Outlook, By Subcutaneous (2022-2030) ($MN)
  • Table 21 Global Patient-derived Xenograft Model Market Outlook, By Orthotopic (2022-2030) ($MN)
  • Table 22 "Global Patient-derived Xenograft Model Market Outlook, By Surgical Implantation (2022-2030) ($MN)
  • Table 23 Global Patient-derived Xenograft Model Market Outlook, By Non-surgical Implantation (2022-2030) ($MN)
  • Table 24 Global Patient-derived Xenograft Model Market Outlook, By Application (2022-2030) ($MN)
  • Table 25 Global Patient-derived Xenograft Model Market Outlook, By Preclinical Drug Development (2022-2030) ($MN)
  • Table 26 Global Patient-derived Xenograft Model Market Outlook, By Biomarker Analysis (2022-2030) ($MN)
  • Table 27 Global Patient-derived Xenograft Model Market Outlook, By Biobanking (2022-2030) ($MN)
  • Table 28 Global Patient-derived Xenograft Model Market Outlook, By Translational Research (2022-2030) ($MN)
  • Table 29 Global Patient-derived Xenograft Model Market Outlook, By End User (2022-2030) ($MN)
  • Table 30 Global Patient-derived Xenograft Model Market Outlook, By Pharmaceutical & Biotechnology Companies (2022-2030) ($MN)
  • Table 31 Global Patient-derived Xenograft Model Market Outlook, By Academic & Research Institutions (2022-2030) ($MN)
  • Table 32 Global Patient-derived Xenograft Model Market Outlook, By Contract Research Organizations (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.